Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations

Join us in this episode of the Oncology Brothers podcast as we dive deep into the rapidly evolving treatment landscape for metastatic non-small cell lung cancer (NSCLC) with actionable mutations in frontline therapy. Hosted by community oncologists Drs. Rahul and Rohit Gosain, we are thrilled to welcome Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins Hospital. In this episode, we covered: •⁠ ⁠Common EGFR mutations and the latest treatment options, including osimertinib, amivantamab, and chemotherapy combinations. •⁠ ⁠The importance of comprehensive NGS testing and the need for retesting at progression. •⁠ ⁠Insights into managing side effects associated with various therapies, including the proactive management of cutaneous toxicities. •⁠ ⁠Treatment strategies for less common mutations such as ALK, ROS1, BRAF, and RET, along with their respective targeted therapies. •⁠ ⁠The role of immunotherapy in specific mutations and the importance of patient choice and preferences in treatment decisions. Whether you're a practicing oncologist or simply interested in the latest advancements in cancer treatment, this episode is packed with valuable information to help guide your practice. Spotify: https://open.spotify.com/episode/3p8r... Apple Podcast: https://podcasts.apple.com/us/podcast... Follow us on social media: •⁠ ⁠X/Twitter:   / oncbrothers   •⁠ ⁠Instagram:   / oncbrothers   •⁠ Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!